All Oncology News

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses the emergence of triplet therapy of ADT, AR-targeted therapy, and cytotoxic chemotherapy for patients with mHSPC; highlights key trials that have explored and supported the use of these triplets; and expands on the unanswered questions that remain regarding patient selection and chemotherapy eligibility.

Vivek K. Narayan, MD, MS, spotlights 3 case studies of patients with metastatic prostate cancer, delving into the influence of their unique mutational status on treatment decisions, scenarios in which to utilize PARP inhibitor monotherapy vs combination regimens, and key trials that support the use of each approach.

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology Congress 2023 in Madrid, Spain.

The novel mRNA biomarkers in the noninvasive ColoAlert® screening test displayed sensitivity and specificity for detecting colorectal cancer and advanced adenomas that could be precursors to CRC.

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

The addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies.

Francisco Javier Esteva, MD, PhD, discusses the management of early-stage HER2-positive breast cancer with a focus on de-escalation strategies, emphasizes the ongoing efforts to de-escalate chemotherapy without compromising effective treatments, and expands on the ongoing debate regarding the role of carboplatin in this setting.

Sneha Phadke, DO, MPH, expands on the investigation of trastuzumab deruxtecan as a possible treatment option for patients with HER2-positive breast cancer who have high-risk residual disease following neoadjuvant systemic therapy.

A new study led by Yale scientists shows that the activity of a portion of a human papillomavirus protein does not depend on its amino acid sequence or composition.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding the approval of a Type II variation application for rucaparib as a frontline maintenance in patients with advanced ovarian cancer who have responded to first-line, platinum-based chemotherapy, irrespective of BRCA mutational status.

The European Medicines Agency’s Committee for Orphan Medical Products has granted orphan drug designation to LSTA1 for the treatment of patients with pancreatic cancer.

Lubna Chaudhary, MD, MS, discusses how findings from the various DESTINY-Breast trials affected the treatment landscape in HER2-positive breast cancer, the trials’ impact on the treatment arena, the evolving treatment landscape for patients with HER2-positive breast cancer, and the importance of staying updated on new drugs and clinical trials.

The FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.

The FDA has approved pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment for patients with resectable non–small cell lung cancer.

Neoadjuvant treatment with intratumoral daromun led to a statistically significant and clinically meaningful improvement in recurrence-free survival compared with surgery alone in patients with locally advanced, fully resectable melanoma, meeting the primary end point of the phase 3 PIVOTAL trial.

Joachim G. J. V. Aerts, MD, PhD, discusses how dendritic cell vaccines could bolster historically poor responses to immunotherapy in patients with mesothelioma, reports and provides potential explanations for negative results from the DENIM trial, and details a potential role for this therapy in earlier lines of mesothelioma treatment.

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of dostarlimab plus chemotherapy for the treatment of adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Florida Cancer Specialists & Research Institute, LLC Director of Drug Development Manish Patel, MD is the co-author for two manuscripts published in the New England Journal of Medicine within two months.

The FDA has granted priority review to the supplemental new drug application seeking the approval of osimertinib in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

The European Commission has approved pembrolizumab as adjuvant monotherapy for the treatment of adult patients with non–small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.

Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.

Montefiore Einstein Comprehensive Cancer Center opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place.

R. Lor Randall, MD discusses the primary results of the PARITY study and their implications for the use of antibiotics for patients with lower extremity bone tumors undergoing surgery and highlighted the findings from the secondary analysis of the study on the effect of surgical duration on risk of infection

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome Board-certified hematologist and medical oncologist Tarek Eldawy, MD to the statewide practice.

Treatment with the combination of ceralasertib and durvalumab elicited preliminary efficacy signals in patients with advanced non–small cell lung cancer with and without RAS mutations who received prior treatment with immune checkpoint blockade.

The FDA has approved nivolumab (Opdivo) for the adjuvant treatment of adult and pediatric patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

Lirafugratinib demonstrated clinical activity in multiple subsets of patients with FGFR2-altered solid tumors, including those with FGFR2-altered hormone receptor–positive, HER2-negative breast cancer.

The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for pembrolizumab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.